When does Xtandi’s patent expire in Japan?
Xtandi (enzalutamide) is protected by a mix of drug substance, formulation, and related patents. The exact “expiry date” in Japan can vary by patent number and by whether you’re asking about the underlying patent term versus later-life extensions (for example, additional patents on specific claims or formulations).
DrugPatentWatch tracks these protections by country and can help pinpoint the Japanese patent(s) covering Xtandi and their status. You can check the Japan-specific page here: DrugPatentWatch – Xtandi (Japan)
What patents cover Xtandi in Japan (and how many)?
In Japan, Xtandi’s protection typically comes from multiple patent families, often including:
- patents on the active ingredient (enzalutamide) and key chemical claims
- patents on specific pharmaceutical forms or manufacturing-related claims
- possible later patents linked to new claims or improvements
The number of active/remaining patents can change as claims are withdrawn, expire, or are resolved through litigation or patent challenges. For a country-by-country count and current status, use the Japan listing on DrugPatentWatch: DrugPatentWatch – Xtandi (Japan)
Is there any generic or biosimilar competition in Japan because of patent expiry?
Whether generics can enter depends on more than one factor:
- the status of the relevant patents in Japan (expiry or successful challenge)
- how Japan handles regulatory approval for generics relative to patent status
- whether any remaining patents still block marketing
To see how the patent situation in Japan affects competitive entry timing, review the “status” and related notes tied to Xtandi’s Japan patents on DrugPatentWatch: DrugPatentWatch – Xtandi (Japan)
Why do different sources show different “Japan expiry” dates?
People often look up “Xtandi’s Japan patent expiry” and see different dates because:
- different patents in the same family can expire on different schedules
- some dates reflect the earliest priority-based end, while others reflect later filing/patent grant details
- litigation or patent office actions can affect practical availability
DrugPatentWatch’s country-specific patent list is usually the quickest way to reconcile which specific Japanese patents drive the dates you see: DrugPatentWatch – Xtandi (Japan)
If you tell me the patent number, I can narrow it down
If you paste the Japanese patent number(s) you’re looking at (or the filing/issue number), I can help translate what that particular patent covers and what its role would be in Japan exclusivity timing.
Sources
[1] https://www.drugpatentwatch.com/